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Placebo analgesia involves the endogenous opioid
system, as administration of the opioid antagonist
naloxone decreases placebo analgesia. To investi-
gate the opioidergic mechanisms that underlie
placebo analgesia, we combined naloxone adminis-
tration with functional magnetic resonance imaging.
Naloxone reduced both behavioral and neural
placebo effects as well as placebo-induced re-
sponses in pain-modulatory cortical structures,
such as the rostral anterior cingulate cortex (rACC).
In a brainstem-specific analysis, we observed a
similar naloxone modulation of placebo-induced
responses in key structures of the descending pain
control system, including the hypothalamus, the
periaqueductal gray (PAG), and the rostral ventrome-
dial medulla (RVM). Most importantly, naloxone abol-
ished placebo-induced coupling between rACC and
PAG, which predicted both neural and behavioral
placebo effects as well as activation of the RVM.
These findings show that opioidergic signaling in
pain-modulating areas and the projections to down-
stream effectors of the descending pain control
system are crucially important for placebo analgesia.
INTRODUCTION
Placebo effects are ubiquitous in modern medicine, not only as
a control in randomized controlled trials but also as a subject
of intense study in diverse clinical fields, such as Parkinson’s
disease, depression, immune function, and pain (Benedetti
et al., 2005; Enck et al., 2008; Price et al., 2008). One of the
best-studied placebo effects is placebo analgesia, where the
administration of a pharmacologically inert substance has
a pain-relieving effect, presumably due to the subject’s expecta-
tion that a potent analgesic substance is being administered
(Montgomery and Kirsch, 1997; Pascalis et al., 2002; Price
et al., 1999; Vase et al., 2005).Pharmacological challenge studies using the opioid antago-
nist naloxone (Amanzio and Benedetti, 1999; Grevert et al.,
1983; Levine and Gordon, 1984; Levine et al., 1978) and positron
emission tomography (PET) studies using m-opioid selective
tracers (Scott et al., 2008; Wager et al., 2007; Zubieta et al.,
2005) have identified an important role of the endogenous opioid
system in both clinical (Levine and Gordon, 1984; Levine et al.,
1978) and experimental pain (Amanzio and Benedetti, 1999;
Grevert et al., 1983; Scott et al., 2008;Wager et al., 2007; Zubieta
et al., 2005). The tracer PET studies have demonstrated release
of endogenous opioids under placebo analgesia in regions asso-
ciated with pain modulation (Bingel and Tracey, 2008; Fields
et al., 2006), including dorsolateral prefrontal cortex (DLPFC),
rostral anterior cingulate cortex (rACC), and periaqueductal
gray (PAG). Other (neurochemically nonspecific) imaging studies
have shown enhanced responses in the same brain regions
under placebo analgesia (Bingel et al., 2006; Kong et al., 2006;
Petrovic et al., 2002; Wager et al., 2004). Importantly, several
functional magnetic resonance imaging (fMRI) studies and one
PET study have also demonstrated placebo-induced signal
decreases in pain-sensitive brain regions, such as thalamus,
insula, and dorsal anterior cingulate cortex (Bingel et al., 2006;
Lieberman et al., 2004; Price et al., 2007; Wager et al., 2004),
most likely related to the pain reduction experienced under
placebo.
With regard to an underlying mechanism that can explain
these observations, it has been hypothesized that placebo anal-
gesia recruits the opioidergic descending pain control system
(Basbaum and Fields, 1984; Fields et al., 2006; Millan, 2002),
the activation of which leads to inhibition of nociceptive process-
ing at the level of the spinal cord and thus to reduced neural
responses in pain-responsive brain regions and a concurrently
reduced pain experience. This pain control network presumably
includes cortical structures, such as the DLPFC and rACC, but
also includes the amygdala, hypothalamus, PAG, and rostral
ventromedial medulla (RVM). The above-mentioned fMRI and
tracer PET studies have provided evidence for DLPFC, rACC,
and, in some cases, PAG involvement in placebo analgesia,
and behavioral findings suggest a spinal component (Matre
et al., 2006). However, conclusive evidence for the involvement
of the lower opioid system (amygdala, hypothalamus, PAG,
and RVM) and especially its functional relevance (i.e., relationNeuron 63, 533–543, August 27, 2009 ª2009 Elsevier Inc. 533
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(A) The experiment took place on two consecutive days
and consisted of three phases: manipulation day 1,manip-
ulation day 2, and test day 2. Before each phase, subjects
were treated with two identical creams on their left fore-
arm. Subjects were told that one creamwas a highly effec-
tive pain reliever, whereas the other served as sensory
control. During the manipulation phases (which consisted
of six trials under placebo cream and control cream,
respectively), painful stimulation on the placebo-treated
patch was surreptitiously lowered (from 80 [score on a
visual analog scale (VAS)] under control to 40 under
placebo) to convince the subjects that they had received
a potent analgesic cream and to create expectations of
future pain relief when treated with this cream. On day 2,
the manipulation phase was carried out inside the (resting)
MR scanner, to reactivate and strengthen the expecta-
tions of pain relief in this context. Before the test phase
started, subjects either received an injection of saline or
naloxone. fMRI data were collected during the test phase,
which consisted of 15 trials under each condition. Impor-
tantly, the strength of painful stimulation was identical on
both skin patches (60 on a VAS), in order to test for
placebo analgesic effects.
(B) Each trial consisted of an anticipation phase (red crosshairs), the painful stimulation, a short pause, the pain rating, and an intertrial interval (ITI). During the ITI,
subjects saw white crosshairs in the center of the screen, which changed color to red at the beginning of the anticipation phase, signaling to the subjects that the
painful stimulation would soon follow. After the painful stimulation, subjects had to rate the pain intensity on a VAS.to pain experience and neural responses in pain-sensitive areas)
is scarce, also because the spatial resolution of previous studies
was less sensitive for the analysis of these small structures.
Testing the hypothesized mechanism of descending pain
control during placebo analgesia requires an experimental
approach that is sensitive to neural responses in pain-encoding
and pain-modulating areas and to their dependence on endoge-
nous opioid neurotransmission. Neither tracer PET nor fMRI
alone can satisfy these two conditions, as tracer PET is not
sensitive to increases or decreases in neural responses (or an
equivalent thereof) and standard fMRI cannot make inferences
about neurochemical events. We therefore employed pharma-
cological fMRI (Honey and Bullmore, 2004; Leslie and James,
2000) in two groups of subjects (n = 48): one receiving the opioid
antagonist naloxone and one receiving saline. This allowed us to
compare both behavioral and blood-oxygen-level-dependent
(BOLD) responses under a ‘‘natural opioid state’’ and a ‘‘blocked
opioid state.’’ To also allow investigation of BOLD responses in
lower brainstem areas, we made use of higher spatial resolution
in comparison to previous imaging studies on placebo-analgesia
and employed a brainstem-dedicated image preprocessing
strategy. We used an established placebo analgesia paradigm
that included an initial expectation manipulation phase and
a later test phase (Price et al., 1999; Wager et al., 2004, 2007;
Figure 1). In a double-blind procedure, naloxone was adminis-
tered just before the test phase, in order to have the same
treatment expectations in both groups.
RESULTS
Placebo Effects in Behavior and BOLD Responses
We first tested whether our experimental manipulation resulted
in a behaviorally measurable placebo analgesic effect and
whether this effect would be reduced in the naloxone group.
Pain ratings showed a significant main effect of condition
(F(1,38) = 30.76, p < 0.001), as well as a significant group-by-
condition interaction (F(1,38) = 5.53, p = 0.01; Figure 2A). More
specifically, while a placebo effect was evident across the whole
sample (23% reduction in pain ratings under placebo compared
to control), this effect was significantly stronger in the saline
Figure 2. Behavioral and Neural Placebo Effects
(A) The pain ratings show that placebo effects are significantly weaker in
the naloxone group. The influence of naloxone is specific for the placebo
condition, as pain ratings under the control condition are almost identical
across groups.
(B) Naloxone also blocks ‘‘neural placebo effects’’ (i.e., reduced BOLD
responses under placebo compared to control), as seen in the parameter
estimates averaged across all pain-responsive regions (see Table S1 for
a list of included regions). *: significant group-by-condition interaction at
p% 0.05. Error bars indicate SEM.534 Neuron 63, 533–543, August 27, 2009 ª2009 Elsevier Inc.
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tion). As can be seen in Figure 2A, the effect of naloxone was
specific for the placebo condition, since the ratings for the
Table 1. BOLD Responses (Control > Placebo) in Pain-
Responsive Regions
Region x y z t Value p Value
Early Pain: Control > Placebo
Saline Group
Basal ganglia 18 8 8 3.47 p < 0.001
Insula 34 0 6 3.18 p < 0.001
Early Pain: Control > Placebo
Saline Group > Naloxone Group
Basal ganglia 12 14 14 3.41 p < 0.001
Basal ganglia 18 8 6 2.86 p < 0.003
Insula 28 24 2 2.69 p < 0.004
Late Pain: Control > Placebo
Saline Group
dACC 0 28 22 3.43 p < 0.001*
Amygdala 28 6 14 3.33 p < 0.001
Insula 48 4 16 2.96 p < 0.002
Basal ganglia 26 8 14 2.87 p < 0.003
Insula 46 18 0 2.83 p < 0.003
Basal ganglia 28 10 2 2.82 p < 0.003*
SI 22 30 56 2.82 p < 0.003
Insula 44 2 4 2.80 p < 0.003
Insula 36 2 6 2.78 p < 0.003
Amygdala 24 2 18 2.73 p < 0.004*
SI 28 28 62 2.71 p < 0.004
Pons 2 32 34 2.68 p < 0.004*
SI 28 28 50 2.65 p < 0.005
Late Pain: Control > Placebo
Saline Group > Naloxone Group
Thalamus 6 16 6 3.81 p < 0.001
Insula 32 14 6 3.45 p < 0.001
Amygdala 30 6 14 3.41 p < 0.001
Insula 46 18 12 3.25 p < 0.001
dACC 4 26 20 3.14 p < 0.001+
Basal ganglia 8 14 10 3.01 p < 0.002
dACC 4 24 22 2.99 p < 0.002
Thalamus 12 12 4 2.86 p < 0.003
SI 28 28 50 2.81 p < 0.003
dACC 8 34 18 2.79 p < 0.003
Basal ganglia 10 10 10 2.67 p < 0.005
SII 36 18 26 2.64 p < 0.005
Thalamus 6 6 2 2.64 p < 0.005+
Contrasts (bold typeface) are listed according to the appearance in the
main text. Coordinates are denoted by x, y, z in mm (MNI-space), and
strength of activation is expressed in t scores (df = 76). dACC, dorsal
anterior cingulate cortex; SI, primary somatosensory cortex; SII,
secondary somatosensory cortex. *p < 0.05 corrected; +p < 0.08 cor-
rected for the dACC and p < 0.06 corrected for the thalamus.control condition did not differ between groups. Skin conduc-
tance responses (SCR) to the painful stimulation showed a signif-
icant group-by-condition interaction in the same direction as the
pain ratings (F(1,37) = 2.91, p = 0.05), again indicating that placebo
analgesia was impaired by naloxone administration.
Next, we tested whether BOLD responses in pain-responsive
brain regions would mirror the behavioral data by showing
reduced activation under the placebo condition compared to
the control condition and whether this difference would in turn
be reduced by naloxone. Based on previous observations, which
showed that placebo effects in BOLD responses are observed in
a late phase of painful stimulation (Price et al., 2007;Wager et al.,
2004), we expected this effect in the second half of the 20 s pain
stimulus. To obtain a global estimate of naloxone influence on
neural placebo effects, we identified pain-responsive brain
regions across both groups by a conjunction analysis (Table
S1) and averaged the parameter estimates across all identified
regions for each subject and condition. This analysis resulted
in a significant group-by-condition interaction during late pain
(F(1,38) = 2.84, p = 0.05; Figure 2B) but not during early pain
(F(1,38) = 0.0003, n.s.), indicating that naloxone significantly
reduced neural placebo effects during late pain.
In a second analysis, we tested which brain regions showed
significant neural placebo effects (i.e., weaker BOLD responses
in the placebo condition than in the control condition) in the
saline group and in which regions naloxone reduced these
effects. During early pain, such effects were only observed in
the insula and the basal ganglia, whereas during late pain such
effects were much more widespread (Table 1): during late pain,
the saline group showed significant neural placebo effects in
the dorsal anterior cingulate cortex (dACC), the amygdala, the
insula, the basal ganglia, the somatosensory cortex, and the
pons. A significant reduction of these effects by naloxone was
observed in the thalamus, the insula, the amygdala, the dACC,
the basal ganglia, and the somatosensory cortex.
Responses in the Descending Pain Control System
More importantly, we investigated whether regions implicated in
descending pain control (DLPFC, rACC, amygdala, hypothal-
amus, PAG, and RVM) would show stronger responses under
placebo as compared to control in the saline group and whether
this differencewould in turn be reduced by naloxone. The DLPFC
showed significant activations under placebo compared to
control (Table 2 and Figure 3a) as well as a modulation by
naloxone. The rACC exhibited two types of responses: at a
more ventral location in subgenual rACC, we observed an
increase in activation under placebo as compared to control
(Table 2 and Figure 3B), whereas in pregenual rACC, we
observed a strong deactivation under placebo as compared to
control (Table 2 and Figure 3C). Only the response in pregenual
rACCwas significantly affected by naloxone. While both types of
rACC responses have been reported in previous fMRI studies on
placebo analgesia (Bingel et al., 2006; Wager et al., 2004),
specifically opioid-dependent deactivations in pregenual rACC
have been linked to antinociceptive processes (Eippert et al.,
2008). Note that the placebo-induced responses in DLPFC and
rACC and their modulation by naloxone were only observed
during early pain, not during late pain (Table 2).Neuron 63, 533–543, August 27, 2009 ª2009 Elsevier Inc. 535
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tivity, we used an additional image preprocessing strategy
optimized for deep-brain structures, including amygdala, hypo-
thalamus, PAG, and RVM (see Experimental Procedures for
details). In contrast to the responses in DLPFC and rACC, which
were only present during the early pain phase in the saline group,
we observed responses in the hypothalamus, PAG, and RVM
that were similarly present during early and late pain (Table
S2). Using a regressor that spanned the entire pain interval
(i.e., 20 s length) resulted in significant activation in the hypothal-
Table 2. BOLDResponses (Placebo >Control) in Pain-Modulatory
Cortical Regions
Region x y z t Value p Value
Early Pain: Placebo > Control
Saline Group
DLPFC 22 12 38 3.78 p < 0.001*
Subgenual rACC 16 36 12 3.70 p < 0.001*
Pregenual rACC 12 38 0 3.44 p < 0.001*
DLPFC 34 12 48 3.03 p < 0.002
DLPFC 24 12 52 2.71 p < 0.004
Subgenual rACC 16 34 14 2.69 p < 0.004
Early Pain: Placebo > Control
Saline Group > Naloxone Group
DLPFC 22 16 38 3.50 p < 0.001+
Pregenual rACC 12 38 0 3.26 p < 0.001+
DLPFC 30 24 28 2.95 p < 0.002
Late Pain: Placebo > Control
Saline Group
— — — — — —
Late Pain: Placebo > Control
Saline Group > Naloxone Group
— — — — — —
Contrasts (bold typeface) are listed according to the appearance in the
main text. Coordinates are denoted by x, y, z in mm (MNI-space), and
strength of activation is expressed in t scores (df = 76). DLPFC, dorsolat-
eral prefrontal cortex; rACC, rostral anterior cingulate cortex. *p < 0.05
corrected; +p < 0.06 corrected for the DLPFC and p < 0.06 corrected
for the pregenual rACC. Note that the pregenual rACC is listed here
although it shows a strong deactivation under placebo.536 Neuron 63, 533–543, August 27, 2009 ª2009 Elsevier Inc.amus (3 9 7, t(76) = 3.34, p < 0.001), the PAG (3 35 17,
t(76) = 2.97, p < 0.002; 1 37 22, t(76) = 2.77, p < 0.004), and
the RVM (5 33 39, t(76) = 2.99, p < 0.002; corresponding
to the reticular nuclei adjacent to the nucleus raphe magnus;
Figure 4). Importantly, the responses in all three regions were
significantly modulated by naloxone (hypothalamus: 3 10
7, t(76) = 2.97, p < 0.002; PAG: 0 38 21, t(76) = 3.05, p <
0.002; RVM:63740, t(76) = 3.58, p < 0.001). Next, we tested
whether the strength of activation of the descending pain control
network was associated with a behavioral marker of placebo
analgesia (i.e., pain ratings). In the saline group, we observed
significant correlations between pain ratings and BOLD
responses in the hypothalamus (4 9 7, t(36) = 3.86, p <
0.001; 1 7 11, t(36) = 3.52, p < 0.001) and the PAG (1 33
11, t(36) = 3.54, p < 0.001), as well as in a region slightly more
rostral to the previously observed RVM activation, possibly rep-
resenting the nucleus raphe pontis (2 35 29, t(36) = 2.68, p <
0.006, trend-level). In all three regions, the correlation was signif-
icantly stronger in the saline group than in the naloxone group
(hypothalamus: 1 6 11, t(36) = 3.88, p < 0.001, 4 10 8,
t(36) = 3.57, p < 0.001; PAG: 1 32 11, t(36) = 3.14, p <
0.002; nucleus raphe pontis:13632, t(36) = 3.07, p < 0.002).
Connectivity between rACC and PAG
As previous studies have reported enhanced connectivity
between rACC and PAG during placebo analgesia (Bingel
et al., 2006; Petrovic et al., 2002; Wager et al., 2007), as well
as during other forms of pain modulation (Valet et al., 2004),
we investigated whether such connectivity is opioid dependent
and can thus be blocked by naloxone. We observed that the
intraindividual coupling between rACC andPAGshowed a signif-
icant main effect of condition (F(1,38) = 5.57, p = 0.01) and a signif-
icant group-by-condition interaction (F(1,38) = 7.73, p < 0.005).
More specifically, in the saline group, rACC-PAG coupling was
enhanced under placebo as compared to control, whereas this
difference was abolished in the naloxone group (Figure 5A).
With regard to the functional relevance of this finding, we
observed that the strength of coupling under placebo showed
a significantly more positive correlation with the behavioral
placebo effect in the saline group than in the naloxone group
(rsaline = 0.28, rnaloxone = 0.33; Z = 1.83; p = 0.03), i.e., the
stronger the placebo-dependent coupling between rACC andFigure 3. BOLD Responses in Cortical Pain
Modulatory Regions
Activation maps (contrast ‘‘early pain: placebo >
control [saline group]’’) and peak voxel parameter esti-
mates show that BOLD responses in (A) the DLPFC
and (B) the subgenual rACC are significantly stronger
under placebo compared to control in the saline
group. This difference is strongly reduced in the
naloxone group. (C) Conversely, the pregenual rACC
shows a strong deactivation under placebo as
compared to control in the saline group, and this
response pattern is significantly different in the
naloxone group. The visualization threshold for all
images is set to p < 0.005 uncorrected and activation
maps are displayed on the average structural image
over all subjects. Error bars indicate SEM.
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group. Complementary to that, the strength of rACC-PAG
coupling under placebo predicted placebo-dependent reduc-
tions in contralateral secondary somatosensory cortex BOLD
responses in the saline group (44 18 30, t(36) = 3.40, p <
0.001; 38 16 26, t(36) = 3.13, p < 0.002; Figure 5B), and this
relationshipwas significantly stronger than in the naloxone group
(4418 28, t(36) = 4.80, p < 0.001 [p < 0.01 corrected]; 4614 26,
t(36) = 3.96, p < 0.001 [p < 0.03 corrected]).
Figure 4. Midbrain and Brainstem BOLD Responses in Areas of the
Descending Pain Control System
(A) The sagittal slice (contrast ‘‘pain: placebo > control [saline group]’’) shows
placebo-enhanced responses in the hypothalamus, the PAG, and the RVM, all
of which are significantly reduced by naloxone. The three transverse slices
show the location of these responses in more detail: (B) hypothalamus, (C)
PAG, (D) RVM. The response in the RVM corresponds to the reticular nuclei
(RN; approximately indicated by the white circle) adjacent to the nucleus raphe
magnus (NRM), which consist of the nucleus reticularis gigantocellularis (more
medial) and the nucleus reticularis parvocellularis (more lateral). (E) The
anatomical drawing indicates the location of these structures (modified from
Naidich et al. [2009]; with permission). The visualization threshold is set to
p < 0.01 uncorrected, and the activation maps are displayed on the average
structural image over all subjects.Finally, if rACC-PAG coupling is involved in descending pain
control, the strength of this coupling should also influence the
activity of the RVM, which directly controls nociceptive process-
ing in the dorsal horn. In line with this assumption, the strength of
rACC-PAG coupling under placebo predicted stronger RVM
BOLD responses under placebo compared to control in the
saline group (5 40 40, t(36) = 3.16, p < 0.002), and this rela-
tionship was significantly stronger than in the naloxone group
(5 39 39, t(36) = 3.74, p < 0.001).
DISCUSSION
In summary, we observed that naloxone impaired placebo anal-
gesia on both the behavioral and neural level, blocked placebo-
induced responses in DLPFC, rACC, hypothalamus, PAG, and
RVM, and abolished placebo-enhanced coupling between
rACC and PAG, which predicted both behavioral and neural
placebo effects in the saline group as well as opioid-dependent
activation of the RVM. Our results thus delineate specific opioi-
dergic mechanisms that configure placebo analgesia and that
are disrupted by naloxone.
Previous behavioral studies have shown naloxone administra-
tion to impair placebo-dependent pain reduction (Amanzio and
Benedetti, 1999; Grevert et al., 1983; Levine and Gordon,
1984; Levine et al., 1978). We observed a similar behavioral
effect of naloxone, which we found to be manifested neuronally
by a blockade of placebo-induced decreases in BOLD re-
sponses in pain-sensitive brain regions. It is interesting to note
that naloxone did not block subjective placebo effects (i.e.,
decrease in pain ratings) completely. This might either imply an
additional nonopioidergic component (Amanzio and Benedetti,
1999; Gracely et al., 1983; Grevert et al., 1983; Vase et al.,
2005), in line with recent imaging and behavioral data implicating
dopamine in experimental placebo analgesia (Schweinhardt
et al., 2009; Scott et al., 2007, 2008), or it could be related to
self-consistency bias and related cognitive processes (KongFigure 5. Connectivity of rACC and PAG
(A) The midline sagittal slice (left) depicts the approximate location of rACC and PAG. The intraindividual coupling between rACC and PAG (as represented by the
correlation between the respective BOLD time courses) is significantly stronger under placebo than under control in the saline group, whereas this difference is
abolished in the naloxone group. Error bars indicate SEM.
(B) The intraindividual rACC-PAG coupling strength under placebo was used to predict decreases in BOLD responses in pain-sensitive regions under placebo
compared to control. The activation map on the left shows that contralateral SII BOLD responses are negatively influenced by rACC-PAG coupling. The plot on
the right illustrates that the stronger the coupling between rACC and PAG, the stronger the reduction in BOLD responses in SII under placebo compared to control
in the saline group (this relationship is significantly different from the naloxone group); the y axis represents difference scores (placebo-control). The visualization
threshold is set to p < 0.005 uncorrected, and the activation map is displayed on the average structural image over all subjects.Neuron 63, 533–543, August 27, 2009 ª2009 Elsevier Inc. 537
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interpretation because physiological placebo effects (SCR and
BOLD) were not evident in the naloxone group. We observed
that neural placebo effects (i.e., placebo-dependent reduction
of pain-related BOLD responses) and their reversal by naloxone
weremost evident in the late pain phase. This suggests that early
heat-pain responses are rather opioid insensitive, an idea sup-
ported by both behavioral data (Borras et al., 2004) and the
rather slow dynamics of opioidergic neurotransmission (Padlub-
naya et al., 2006).
The placebo-dependent reduction of BOLD responses and its
reversal by naloxone was most evident in dorsal anterior cingu-
late cortex. A modulation of this region has been shown not only
in studies on placebo analgesia (Lieberman et al., 2004; Price
et al., 2007; Wager et al., 2004) but also in various other condi-
tions, such as attentional manipulations (Bantick et al., 2002),
expectation manipulations (Keltner et al., 2006), and hypnosis
(Rainville et al., 1997). In line with a recent study on conditioned
hypoalgesia (Eippert et al., 2008), our results suggest that a
downregulation of dorsal anterior cingulate cortex depends on
opioidergic neurotransmission. The widespread reductions of
BOLD responses in pain-sensitive regions (both subcortical
and cortical) under placebo and their reversal by naloxone go
along with effects observed under exogenous opiate administra-
tion (Casey et al., 2000; Wagner et al., 2007), suggesting that
afferent inhibition at the level of the spinal cord via descending
pain control might be one mechanism underlying placebo anal-
gesia. This is in line with recent behavioral studies showing
that expectations regarding pain can alter spinal nociceptive
processing (Goffaux et al., 2007; Matre et al., 2006).
With regard to areas involved in painmodulation and descend-
ing pain control (Basbaum and Fields, 1984; Bingel and Tracey,
2008; Fields et al., 2006; Millan, 2002), we observed placebo-
enhanced DLPFC as well as rACC responses during painful
stimulation that were reduced by naloxone. As placebo anal-
gesia is most likely the result of several different neurobiological
mechanisms (Kong et al., 2006, 2007), it is entirely possible that
cortico-cortical interactions (i.e., direct influences from DLPFC
or rACC on pain-sensitive areas; see also Craggs et al. [2007])
underlie the observed neural and behavioral placebo effects.
However, in addition to opioid-dependent DLPFC and rACC
activation, we also observed placebo-induced BOLD responses
in the hypothalamus, the PAG, and the RVM, which taken
together constitute a phylogenetically conserved system of de-
scending pain control acting at the level of the spinal cord
(Basbaum and Fields, 1984; Fields et al., 2006; Millan, 2002).
The opioid-dependent responses in these areas do not merely
represent an epiphenomenon, but are of functional relevance,
as responses in these areas were related to behavioral placebo
effects.
As wemapped the whole hierarchy of descending pain control
structures (from DLPFC to RVM), we also attempted to link
cortical and brainstem responses. Since there is direct anterior
cingulate input to the PAG (An et al., 1998; Floyd et al., 2000)
and as previous studies observed heightened rACC-PAG func-
tional connectivity under placebo analgesia (Bingel et al., 2006;
Petrovic et al., 2002; Wager et al., 2007), we wanted to test
whether these connections are opioid dependent. We observed538 Neuron 63, 533–543, August 27, 2009 ª2009 Elsevier Inc.placebo-enhanced coupling between the rACC and the PAG,
which was abolished by naloxone. In agreement with the finding
that electrical PAG stimulation leads to profound opioid-depen-
dent analgesia in humans (Hosobuchi et al., 1977), we could
show that placebo-enhanced rACC-PAG connectivity is of func-
tional relevance, as it predicted both behavioral (as measured by
pain ratings) and neural placebo effects (as measured by BOLD
responses in secondary somatosensory cortex). The main route
of descending control from the PAG is via the RVM to the dorsal
horn of the spinal cord (e.g., via direct PAG connections to
spinally projecting RVM neurons [Morgan et al., 2008]). We
therefore tested whether rACC-PAG coupling would drive RVM
BOLD responses and observed that the strength of rACC-PAG
coupling indeed predicted opioid-dependent RVM activation.
With regard to the temporal occurrence of responses in
regions of the descending pain control system, it is interesting
to note that cortical responses in DLPFC and rACCwere present
during early pain but not during late pain, and thus preceded
placebo-induced reductions of BOLD responses in the pain
matrix. Subcortical responses in the hypothalamus, PAG, and
RVM were however present during both early and late pain. In
combination with the observed effects on rACC-PAG coupling,
we tentatively suggest the following mechanism. Upon painful
stimulation, treatment expectations regarding the analgesic
efficacy of the placebo cream need to be ‘‘kept in mind’’ and
pain needs to be ‘‘kept out of mind’’ (Bunge et al., 2001; Lorenz
et al., 2003). Such maintenance and selection processes have
extensively been associated with the DLPFC (Miller, 2000; Miller
and Cohen, 2001). Via opioid-dependent signaling, the DLPFC
will recruit areas such as rACC that can engage the lower parts
of the descending pain control system through their projections.
The lower part of the descending pain control system (hypothal-
amus, PAG, and RVM) will then exert an opioid-dependent inhib-
itory influence on spinal nociceptive processing, leading to
reduced nociceptive input to thalamic and cortical areas and
thus to a reduced pain experience. This inhibitory brainstem
control, once initiated via cortical input, will persist until the noci-
ceptive input is terminated, possibly supported by feedback
signals relayed via ascending spinobulbar or spinohypothalamic
projections.
It will be interesting to see whether opioid-dependent activa-
tion of the descending pain control system is a common feature
of different forms of pain modulation, such as hypnosis, atten-
tional distraction, reappraisal, and placebo analgesia, which
share some common neuroanatomical features (Benedetti
et al., 2005; Ochsner and Gross, 2005; Petrovic and Ingvar,
2002; Wiech et al., 2008) and act inhibitory (Kiernan et al., 1995;
Matre et al., 2006; Willer et al., 1979) on nociceptive processing
in the spinal cord.
EXPERIMENTAL PROCEDURES
Subjects
Forty-eight german male volunteers (mean age: 26.13 years; range: 20–40
years) were assigned to two groups on a randomized double-blind basis.
The experimental group received the opioid antagonist naloxone (‘‘naloxone
group’’), whereas the control group received saline (‘‘saline group’’). Groups
did not differ with respect to age, weight, personality scores, and basic pain
sensitivity (see Supplemental Experimental Procedures and Results). Data
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mental Procedures and Results). The Ethics Committee of the Medical Board
in Hamburg, Germany, approved the study and all subjects gave written
informed consent. The consent form included information about the experi-
mental procedures, the MR procedure, the thermal stimulation, and the
possible adverse effects of naloxone. The consent form did not include state-
ments that subjects would be deceived and that the purpose of the study was
to investigate placebo analgesia. Subjects were informed about these impor-
tant aspects only during debriefing.
Drug Administration
At15 min before the start of the test phase, we administered a bolus dose of
0.15 mg/kg naloxone (Naloxon-ratiopharm, Ratiopharm, Ulm, Germany) or
saline via an intravenous line inserted into the antecubital vein of the left arm.
Because naloxone has a relatively short half-life (70 min in blood plasma;
Summary of Product Characteristics, Ratiopharm) and its clinically effective
duration of action can be even shorter (Gutstein and Akil, 2006), we also admin-
istered an intravenous infusion dose of 0.2mg/kg/hr naloxone or saline (diluted
in 250 ml of saline), starting shortly after bolus administration. This dosing
regime leads to a stable concentration of naloxone in blood plasma over the
length of the experiment (E.D.S. et al., unpublished data) and is sufficient to
block central opioid receptors completely (Mayberg and Frost, 1990).
Subjects were informed about naloxone, including its pharmacological
properties, its general clinical use, and its possible side effects. Subjects
were also informed that they would most likely not notice that they had
received naloxone, as (in the dose employed here) it generally does not have
effects on mood and experimental phasic pain stimulation (Grevert and Gold-
stein, 1978; Petrovic et al., 2008). Naturally, we could not inform subjects
about the true purpose of naloxone administration in this study (this was
done during debriefing). We therefore told them that they would receive
naloxone because its pharmacological properties allowed us to visualize
where in the brain pain-specific responses would occur.
The experimenters who interacted with the subjects (U.B. and J.Y. adminis-
tered the drug [i.e., either naloxone or saline]; F.E. carried out the experiments)
were blinded as to which drug was given. E.D.S. and two research assistants,
who did not interact with the subjects, carried out the assignment of subjects
to the two groups and the naloxone handling. Unblinding occurred only after
the experiment.
Study Design
We used a between-subjects design, because placebo effects are also
shaped by prior experience (Colloca and Benedetti, 2006), which could
strongly confound results obtained in a within-subjects design. Subjects
were recruited with the understanding that this study investigated the influence
of an analgesic cream (‘‘lidocaine [2%], an extremely effective pain killer, which
at higher doses even acts as a local anesthetic’’) on brain responses to painful
stimulation. The design of this study followed a well-established placebo anal-
gesia paradigm including both expectation and conditioning components
(Figure 1A) (Colloca and Benedetti, 2006; Colloca et al., 2008; Klinger et al.,
2007; Montgomery and Kirsch, 1997; Price et al., 1999; Wager et al., 2004).
On day 1, subjects came into the building housing the MR scanner (situated
on the campus of the university hospital) andwere greeted by the experimenter
wearing a white lab coat. They were then led into a medical examination room
and were familiarized with the thermal stimulation by presenting them with
several stimuli of varying duration and temperature on their right forearm.
Subsequently, they were informed about the experimental procedures, and
five 4 3 4 cm squares were drawn on their left volar forearm. The two upper/
lower squares were outlined in green/red color and designated as the site
for later placebo cream/control cream stimulation; the coloring was chosen
to enhance the association between skin patch and pain relief. The middle
square was used for calibrating the thermal stimulation, i.e., to find tempera-
tures corresponding to 40, 60, and 80 on a visual analog scale (VAS; 100 parts;
endpoints labeled with ‘‘no pain’’ and ‘‘unbearable pain’’): subjects were stim-
ulated with a pseudorandom sequence of 20 s thermal stimuli with different
intensities and were asked to rate the intensity of each stimulus. We then
used regression analysis to estimate the temperatures corresponding to inten-
sity levels of 40, 60, and 80 on the VAS. This ensured that each subject wouldbe stimulated with individually tailored stimulus intensities that are however
comparable across subjects on the VAS.
Upon termination of the calibration procedure, we treated subjects with two
identical creams, which were however presented as ‘‘lidocaine cream’’ and
‘‘control cream’’ and were kept in professionally labeled tubes. We told
subjects that they would receive lidocaine cream on the skin areas outlined
in green and that they would receive a completely inactive sensory control
cream on the skin areas outlined in red. They were furthermore told that
the experiment would only start after 10 min, because of ‘‘the time it takes
for lidocaine to become fully effective.’’ During these 10 min, subject filled
out three questionnaires (Beck Depression Inventory, State-Trait Anxiety
Inventory, and Crowne-Marlowe Social Desirability Scale).
Afterward, the manipulation phase started. Subjects were told that they
would be stimulated on both skin patches (placebo cream, control cream)
with 80% of their pain tolerance (i.e., right-hand end of VAS), but unbeknownst
to them the temperature was lowered to 40% of their pain tolerance during the
placebo condition. This served to convince subjects that the placebo cream is
an effective analgesic substance against heat pain stimulation and to enhance
their expectations regarding future treatment with the placebo cream. The
manipulation phase consisted of two sessions (stimulation of skin patch
treated with control cream and stimulation of skin patch treated with placebo
cream) with six trials each. Each trial consisted of anticipation, pain, pause,
rating, and rest (Figure 1B). At the start of the anticipation phase, awhite cross-
hair changed color to red, which signaled to the subjects that painful stimula-
tion would follow soon. Subjects had to press a button as fast as possible
when the crosshair changed color. After a variable delay (7.5 ± 3.5 s), a 20 s
painful thermal stimulus was administered (1.5 s ramp up, 17 s plateau,
1.5 s ramp down). A variable delay (5 ± 2 s) followed the thermal stimulation,
before subjects had to rate the level of pain present on that trial using a VAS.
A variable intertrial interval (ITI; 20 ± 5 s) followed, during which a white cross-
hair was displayed. Before each session, pain thresholds were assessed using
the method of limits. We slowed down the rise time of the thermode on the
placebo-treated skin patch (from 1.2/s in the control condition to 0.7/s in
the placebo condition), in order to give the subjects a first hint of the efficacy
of the placebo cream. After the manipulation phase, subjects had to indicate
how effective they perceived the ‘‘lidocaine cream’’ to be for pain reduction
(on a scale from 0 [no pain reduction] to 5 [extremely strong pain reduction]).
The assignment of placebo cream or control cream to the upper or lower
patches was randomized across subjects, such that half of the subjects
received the placebo cream on the upper patches and the other half received
placebo cream on the lower patches. Similarly, which patch (placebo cream or
control cream) was stimulated first was also randomized, to prevent a con-
founding effect of order (Wager et al., 2006; Price et al., 2007). Finally, which
of the two placebo (or control) treated patches would be stimulated in the first
manipulation session was also randomized. Similar to a previous study (Wager
et al., 2004), we used two patches for each condition to prevent stimulation of
the same patch during manipulation and test on day 2.
On day 2, subjects were first tested for current alcohol and drug use
(including THC and opiates) using commercially available saliva and urin tests
(Diagnostik-Nord, Schwerin, Germany). Subjects then received the two
creams on the respective skin areas, which had again been outlined by green
and red color. After a waiting period of 10 min (to allow ‘‘lidocaine to become
effective’’), they were placed inside the MR scanner, where a further manipu-
lation phase with six trials for each condition took place without scanning.
Subjects were told that this phase served to make them comfortable with
being in the MR scanner, whereas in reality it mainly served to reactivate
and strengthen expectations of pain relief due to the placebo cream (i.e., to
maximize the positive experience of placebo prior to test [Colloca and Bene-
detti, 2006; Colloca et al., 2008]). After this manipulation phase, subjects rated
the analgesic efficacy of the placebo cream, received a refreshment of the
placebo and control cream, and then received a bolus injection of either
naloxone or saline. Subjects were placed in theMR scanner again, the infusion
of naloxone or saline was started, and 15 min after the bolus administration,
the test phase began. Similar to the manipulation sessions, each test session
was preceded by pain threshold estimation. The test phase consisted of two
sessions (15 trials each) during which fMRI data were recorded: in one session
the skin part treated with placebo cream was stimulated, whereas in the otherNeuron 63, 533–543, August 27, 2009 ª2009 Elsevier Inc. 539
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both sessions subjects were stimulated with the same temperature (equivalent
to 60 on the VAS). This physically identical stimulation allowed for the assess-
ment of placebo effects (i.e., reduced pain ratings under placebo cream
compared to control cream).
After the experiment, we removed the i.v. line and subjects again rated the
analgesic efficacy of the placebo cream and answered two questionnaires
regarding (1) experienced adverse-effects of naloxone and (2) current mood
(see Supplemental Experimental Procedures and Results).
Data Acquisition
We used Presentation software (Neurobehavioral Systems, Albany, CA, USA)
for stimulus presentation and recording of reaction times and pain ratings.
Thermal stimulation was carried out using a thermode (a 30 3 30 mm Peltier
device; TSAII, Medoc, Tel Aviv, Israel).
Skin conductance responses (SCR) were acquired using MRI-safe
electrodes (2700 CLEARTRACE2, CONMED, Utica, NY, USA) attached to
the hypothenar of the subject’s left hand. The same dermatome (C8) was
chosen for both electrodes to control for possible recording differences
between dermatomes. We used a CED 2502 to amplify the skin conductance
signal, a CED micro1401 mkII to digitize the signal at 1000 Hz, and Spike2
software to record the data (all equipment by Cambridge Electronic Design,
Cambridge, UK). Functional magnetic resonance imaging (fMRI) data were
acquired on a 3 Tesla system (Siemens Magnetom Trio, Siemens, Erlangen,
Germany) equipped with a 12 channel head coil. Forty-four transversal slices
(slice thickness, 2 mm; gap, 1 mm) were acquired in each volume (repetition
time: 2.62 s, echo time: 25 ms, flip angle: 90, field of view: 208 3 208 mm,
matrix: 104 3 104; GRAPPA with PAT-factor 2 and 48 reference lines) using
T2*-weighted echo-planar imaging (EPI). Slice orientation was tilted by
39, which allowed coverage of areas as ventral as the medulla. The first
five volumes of each session were discarded to allow for T1 saturation. We
also acquired high-resolution (1 3 1 3 1 mm voxel size) T1-weighted images
for each subject using a MP-RAGE sequence (in two subjects, high-resolution
images could not be acquired due to time constraints).
Data Analysis: Behavior
All behavioral data were analyzed in MATLAB (The MathWorks, Natick, MA,
USA) or STATISTICA (StatSoft, Tulsa, OK, USA), using a threshold of p %
0.05 (one-tailed in cases of a priori hypotheses). Pain ratings were analyzed
using a two-way analysis of variance (ANOVA) with between-subject factor
group (saline and naloxone) and within-subject factor condition (control and
placebo). We used separate ANOVAs for pain ratings in the first manipulation
session, the second manipulation session, and the test session. Postexperi-
mental ratings regarding the analgesic efficacy of the placebo cream were
analyzed using a two-sample t test.
Skin conductance responses (SCR) could not be acquired from one subject
due to technical problems. Data from the remaining subjects were resampled
to 10 Hz and smoothedwith a 1 s (full width at half maximum, FWHM)Gaussian
kernel. For SCR analysis during pain, we used a time interval of 25 s, starting at
pain onset. Amplitudes were determined as the maximum in the analysis
interval in relation to a preceding minimum in the analysis interval. Before
statistical analysis, amplitudes were z transformed. SCR amplitudes were
analyzed using a two-way ANOVA with between-subject factor group (saline
and naloxone) and within-subject factor condition (control and placebo).
Data Analysis: fMRI
fMRI data processing and statistical analyses were carried out using statistical
parametric mapping (SPM5, Wellcome Trust Centre for Neuroimaging, Lon-
don, UK). Data processing consisted of slice timing (correction for differences
in slice acquisition time), realignment (motion correction), spatial normalization
to a standard EPI template, and smoothing with an 8 mm (FWHM) isotropic
Gaussian kernel. Data were also subjected to high-pass filtering (cutoff period:
128 s) and correction for temporal autocorrelations (based on a first-order
autoregressive model).
Data analysis was performed using a general linear model approach. The
first-level design matrix of each subject included ten regressors (five in each
session): anticipation placebo, anticipation control, pain-early placebo, pain-540 Neuron 63, 533–543, August 27, 2009 ª2009 Elsevier Inc.early control, pain-late placebo, pain-late control, rating placebo, rating
control, and two session constants. Anticipation was modeled by convolving
a delta function (at anticipation onset) with the canonical hemodynamic
response function (HRF), pain-early was modeled by convolving a 10 s boxcar
function (starting at pain onset) with the canonical HRF, pain-late wasmodeled
by convolving a 10 s boxcar function (starting 11 s after pain onset) with the
canonical HRF, and rating was modeled by convolving delta functions (repre-
senting each button press during rating) with the canonical HRF. The painful
stimulation was divided into early and late periods based on previous results
regarding neural placebo effects (Price et al., 2007; Wager et al., 2004) and
naloxone function (Borras et al., 2004). After model estimation, the ensuing
first-level contrast images from each subject were used for second-level
analysis. Second-level design matrices were configured using SPMs ‘‘full
factorial’’ model and included four regressors (e.g., saline group: pain-early
placebo, saline group: pain-early control, naloxone group: pain-early placebo,
naloxone group: pain-early control). We corrected for possible nonsphericity
of the error term (dependence of conditions and possible unequal variance
between groups). In the following, we list analyses as they appear in the
main text. When speaking of neural placebo effects, we refer to reduced
BOLD responses under the placebo condition as compared to the control
condition. Note that the main interest of this study concerned responses
during the pain period and data from the anticipation phase are therefore
presented in the Supplemental Experimental Procedures and Results.
In a first analysis testing for ‘‘global placebo effects,’’ we investigated the
overall influence of naloxone on neural placebo effects. Therefore, we identi-
fied all regions that showed significant BOLD responses to painful stimulation
during the control condition in both groups via a conjunction analysis (Nichols
et al., 2005). We then extracted parameter estimates from each region (6 mm
sphere around peak voxel) for both conditions (control and placebo) from each
subject, averaged the parameter estimates across all regions on a subject-by-
subject basis and finally calculated a two-way ANOVA with between-subject
factor group (saline and naloxone) and within-subject factor condition (control
and placebo) over the averaged parameter estimates. This analysis was
carried out separately for early-pain (first 10 s of 20 s pain period) and late-
pain (last 10 s of 20 s pain period).
In a second analysis, we tested for regionally specific neural placebo effects
and their modulation by naloxone. We thus used the contrast ‘‘saline group:
control > placebo’’ to test for effects in the saline group and the interaction
contrast ‘‘(saline group: control > placebo) > (naloxone group: control >
placebo)’’ to test for a group-by-condition interaction. These analyses were
also carried out separately for early-pain and late-pain.
We also investigated placebo-enhanced BOLD responses in pain modula-
tory structures and their modulation by naloxone. To this end, we used the
contrast ‘‘saline group: placebo > control’’ to test for effects in the saline group
and the contrast ‘‘(saline group: placebo > control) > (naloxone group: placebo
> control)’’ to test for a group-by-condition interaction. Again, these analyses
were carried out separately for early pain and late pain.
To further investigate such effects at the subcortical level with higher sensi-
tivity, we used an additional image preprocessing strategy optimized for deep-
brain structures, including amygdala, hypothalamus, PAG, and RVM. We first
created a mask (box) of the following dimensions (30:30, 60:0, 72:0, x y z
in mm). Voxels in the mask were set to one, and voxels outside the mask were
set to zero. To optimize the normalization procedure for the lower structures
(especially the brainstem), we weighted the normalization cost function
with this mask; only affine transformations were used. A similar procedure
(Napadow et al., 2006) has been shown to significantly improve brainstem
coregistration accuracy. Normalized images were resliced at a resolution of
1 3 1 3 1 mm and were smoothed with a 4 mm FWHM isotropic Gaussian
kernel to preserve the fine-scale structure. Note that weighting the motion-
correction cost-function with the same box (also combined with increasing
the spatial sampling rate and masking out highly variant regions, such as
blood-vessels) did not lead to a consistent increase in sensitivity and was
therefore omitted. Instead we used standard motion-correction as done in
the original analysis. Statistical analyses were carried out as described above,
but also using a regressor that spanned the entire pain interval (20 s). We also
investigatedwhether behavioral placebo effects (i.e., difference in pain ratings)
would predict placebo-induced increases in BOLD responses in the
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ratings (control-placebo) as a covariate in a two-sample t test on the second
level, testing whether a greater rating difference would lead to stronger
BOLD responses (placebo compared to control) in the saline group, but not
in the naloxone group.
To test for rACC-PAGconnectivity,we first anatomically defined a seedvoxel
in the center of the PAG, as identified on the average high-resolution image of
our subjects. The PAG was used for seed voxel identification because in
contrast to rACC, the PAG borders can readily be identified on a structural
scan, which allows easy identification of the geometric center of this structure.
The following coordinates were found to be the geometric center of the PAG:
x = 0, y =32, z =10. We then set a sphere of 6 mm radius around this coor-
dinate and extracted the mean time series for each subject under each condi-
tion. These time series were then used as sole predictors in subject-specific
design matrices and contrasts were computed that tested for placebo >
control. Contrast images were subsequently raised to the second level, where
we observed a significant effect in the saline group (16 44 0, t(76) = 4.04, p <
0.001 [p = 0.01 corrected]) as well as a significant group-by-condition interac-
tion in rACC (16 44 0, t(76) = 3.47, p < 0.001 [p = 0.05 corrected]). However, as
such an analysis is not necessarily symmetric (Friston et al., 1997) we also
extracted the mean time series of a 6 mm sphere around the observed rACC
coordinate and then correlated the two time series. The resulting correlation
coefficients for each condition in each subject were Fisher-z transformed and
subjected to a two-way ANOVA with between-subject factor group (saline
and naloxone) and within-subject factor condition (control and placebo). To
test for the functional relevance of this coupling, we correlated the coupling
strength under placebo (Fisher-z transformed correlation coefficients) with
the behavioral placebo effect (difference between control and placebo for
each subject) and tested whether the saline group would show a significantly
more positive correlation than the naloxone group. A similar analysis was
carried out with the fMRI data, where we used the coupling strength under
placebo as a covariate in a two-sample t test on the second level, investigating
whether greater couplingwould lead to stronger reductions inBOLD responses
(placebo compared to control) in the saline group, but not in the naloxone group
(only tested for late pain). Finally, we used the coupling strength under placebo
as a covariate in a two-sample t test on the second level, investigating whether
greater coupling would lead to stronger RVM BOLD responses (placebo
compared to control) in the saline group, but not in the naloxone group.
We used an initial height threshold of p < 0.005 uncorrected (similar to
previous studies on placebo analgesia [Wager et al., 2004]). We also report
corrected p values as obtained from small volume correction in a priori regions
of interest at a level of p% 0.05. Correction was based on peak coordinates
(ignoring laterality) obtained from previous studies on pain processing and
painmodulation. TheDLPFC (Zubieta et al., 2005)wascorrectedusing asphere
of 15 mm radius. The primary somatosensory cortex (Bingel et al., 2007), the
secondary somatosensory cortex (Bingel et al., 2007), the insula (Bingel
et al., 2007), the dACC (Bu¨chel et al., 2002), the rACC (pregenual part [Eippert
et al., 2008]; subgenual part [Bingel et al., 2007]) were corrected using spheres
of 12 mm radius. The basal ganglia (Bingel et al., 2002), the amygdala (Zubieta
et al., 2005), the thalamus (Zubieta et al., 2001), and the pons (Petrovic et al.,
2004) were corrected using spheres of 6 mm radius. Corrected p values are
not reported for the results of the brainstem-specific analysis (hypothalamus,
PAG, and RVM [which is defined as the nucleus raphe magnus and adjacent
reticular nuclei (Millan, 2002)]), since the descending pain control system has
not been investigated at this level with sufficient spatial resolution, and coordi-
nates for small-volume correction are thus lacking.
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Supplemental Data include Supplemental Experimental Procedures, Supple-
mental Results, four tables, and one figure and can be found with this article
online at http://www.cell.com/neuron/supplemental/S0896-6273(09)00543-1.
ACKNOWLEDGMENTS
This work was supported by a grant from the German Research Foundation
(DFG BU 1323). We thank Wiebke Herken and Andreas Marschner for thenaloxone handling and Katrin Mu¨ller and Kathrin Wendt for help with MR
scanning.
Accepted: July 7, 2009
Published: August 26, 2009
REFERENCES
Amanzio, M., and Benedetti, F. (1999). Neuropharmacological dissection of
placebo analgesia: expectation-activated opioid systems versus condi-
tioning-activated specific subsystems. J. Neurosci. 19, 484–494.
An, X., Bandler, R., Ongu¨r, D., and Price, J.L. (1998). Prefrontal cortical projec-
tions to longitudinal columns in the midbrain periaqueductal gray in macaque
monkeys. J. Comp. Neurol. 401, 455–479.
Bantick, S.J., Wise, R.G., Ploghaus, A., Clare, S., Smith, S.M., and Tracey, I.
(2002). Imaging how attention modulates pain in humans using functional
MRI. Brain 125, 310–319.
Basbaum, A.I., and Fields, H.L. (1984). Endogenous pain control systems:
brainstem spinal pathways and endorphin circuitry. Annu. Rev. Neurosci. 7,
309–338.
Benedetti, F., Mayberg, H.S., Wager, T.D., Stohler, C.S., and Zubieta, J.-K.
(2005). Neurobiological mechanisms of the placebo effect. J. Neurosci. 25,
10390–10402.
Bingel, U., and Tracey, I. (2008). Imaging CNS modulation of pain in humans.
Physiology (Bethesda) 23, 371–380.
Bingel, U., Quante, M., Knab, R., Bromm, B., Weiller, C., and Bu¨chel, C. (2002).
Subcortical structures involved in pain processing: evidence from single-trial
fMRI. Pain 99, 313–321.
Bingel, U., Lorenz, J., Schoell, E., Weiller, C., and Bu¨chel, C. (2006). Mecha-
nisms of placebo analgesia: rACC recruitment of a subcortical antinociceptive
network. Pain 120, 8–15.
Bingel, U., Schoell, E., Herken, W., Bu¨chel, C., and May, A. (2007). Habituation
to painful stimulation involves the antinociceptive system. Pain 131, 21–30.
Borras, M.C., Becerra, L., Ploghaus, A., Gostic, J.M., DaSilva, A., Gonzalez,
R.G., and Borsook, D. (2004). fMRI measurement of CNS responses to
naloxone infusion and subsequent mild noxious thermal stimuli in healthy
volunteers. J. Neurophysiol. 91, 2723–2733.
Bu¨chel, C., Bornhovd, K., Quante, M., Glauche, V., Bromm, B., and Weiller, C.
(2002). Dissociable neural responses related to pain intensity, stimulus inten-
sity, and stimulus awareness within the anterior cingulate cortex: a parametric
single-trial laser functional magnetic resonance imaging study. J. Neurosci.
22, 970–976.
Bunge, S.A., Ochsner, K.N., Desmond, J.E., Glover, G.H., and Gabrieli, J.D.
(2001). Prefrontal regions involved in keeping information in and out of mind.
Brain 124, 2074–2086.
Casey, K.L., Svensson, P., Morrow, T.J., Raz, J., Jone, C., and Minoshima, S.
(2000). Selective opiate modulation of nociceptive processing in the human
brain. J. Neurophysiol. 84, 525–533.
Colloca, L., and Benedetti, F. (2006). How prior experience shapes placebo
analgesia. Pain 124, 126–133.
Colloca, L., Tinazzi, M., Recchia, S., Pera, D.L., Fiaschi, A., Benedetti, F., and
Valeriani, M. (2008). Learning potentiates neurophysiological and behavioral
placebo analgesic responses. Pain 139, 306–314.
Craggs, J.G., Price, D.D., Verne, G.N., Perlstein, W.M., and Robinson, M.M.
(2007). Functional brain interactions that serve cognitive-affective processing
during pain and placebo analgesia. Neuroimage 38, 720–729.
Eippert, F., Bingel, U., Schoell, E., Yacubian, J., and Bu¨chel, C. (2008).
Blockade of endogenous opioid neurotransmission enhances acquisition of
conditioned fear in humans. J. Neurosci. 28, 5465–5472.
Enck, P., Benedetti, F., and Schedlowski, M. (2008). New insights into the
placebo and nocebo responses. Neuron 59, 195–206.
Fields, H.L., Basbaum, A.I., and Heinricher, M.M. (2006). Central nervous
system mechanisms of pain modulation. In Wall and Melzack’s TextbookNeuron 63, 533–543, August 27, 2009 ª2009 Elsevier Inc. 541
Neuron
Placebo Analgesia and Descending Pain Controlof Pain, S.B. McMahon and M. Koltzenburg, eds. (London: Elsevier),
pp. 125–142.
Floyd, N.S., Price, J.L., Ferry, A.T., Keay, K.A., and Bandler, R. (2000). Orbito-
medial prefrontal cortical projections to distinct longitudinal columns of the
periaqueductal gray in the rat. J. Comp. Neurol. 422, 556–578.
Friston, K.J., Buechel, C., Fink, G.R., Morris, J., Rolls, E., and Dolan, R.J.
(1997). Psychophysiological and modulatory interactions in neuroimaging.
Neuroimage 6, 218–229.
Goffaux, P., Redmond, W.J., Rainville, P., and Marchand, S. (2007). Descend-
ing analgesia–when the spine echoes what the brain expects. Pain 130,
137–143.
Gracely, R.H., Dubner, R., Wolskee, P.J., and Deeter, W.R. (1983). Placebo
and naloxone can alter post-surgical pain by separate mechanisms. Nature
306, 264–265.
Grevert, P., and Goldstein, A. (1978). Endorphins: naloxone fails to alter exper-
imental pain or mood in humans. Science 199, 1093–1095.
Grevert, P., Albert, L.H., and Goldstein, A. (1983). Partial antagonism of
placebo analgesia by naloxone. Pain 16, 129–143.
Gutstein, H.B., and Akil, H. (2006). Opioid analgesics. In Goodman and
Gilman’s the Pharmacological Basis of Therapeutics, L.L. Brunton, J.S.
Lazo, and K.L. Parker, eds. (New York, NY: McGraw-Hill), pp. 547–590.
Honey, G., and Bullmore, E. (2004). Human pharmacological MRI. Trends
Pharmacol. Sci. 25, 366–374.
Hosobuchi, Y., Adams, J.E., and Linchitz, R. (1977). Pain relief by electrical
stimulation of the central gray matter in humans and its reversal by naloxone.
Science 197, 183–186.
Keltner, J.R., Furst, A., Fan, C., Redfern, R., Inglis, B., and Fields, H.L. (2006).
Isolating the modulatory effect of expectation on pain transmission: a func-
tional magnetic resonance imaging study. J. Neurosci. 26, 4437–4443.
Kiernan, B.D., Dane, J.R., Phillips, L.H., and Price, D.D. (1995). Hypnotic
analgesia reduces R-III nociceptive reflex: further evidence concerning the
multifactorial nature of hypnotic analgesia. Pain 60, 39–47.
Klinger, R., Soost, S., Flor, H., andWorm,M. (2007). Classical conditioning and
expectancy in placebo hypoalgesia: a randomized controlled study in patients
with atopic dermatitis and persons with healthy skin. Pain 128, 31–39.
Kong, J., Gollub, R.L., Rosman, I.S., Webb, J.M., Vangel, M.G., Kirsch, I., and
Kaptchuk, T.J. (2006). Brain activity associated with expectancy-enhanced
placebo analgesia as measured by functional magnetic resonance imaging.
J. Neurosci. 26, 381–388.
Kong, J., Kaptchuk, T.J., Polich, G., Kirsch, I., and Gollub, R.L. (2007). Placebo
analgesia: findings from brain imaging studies and emerging hypotheses. Rev.
Neurosci. 18, 173–190.
Leslie, R.A., and James, M.F. (2000). Pharmacological magnetic resonance
imaging: a new application for functional MRI. Trends Pharmacol. Sci. 21,
314–318.
Levine, J.D., and Gordon, N.C. (1984). Influence of the method of drug admin-
istration on analgesic response. Nature 312, 755–756.
Levine, J.D., Gordon, N.C., and Fields, H.L. (1978). The mechanism of placebo
analgesia. Lancet 2, 654–657.
Lieberman, M.D., Jarcho, J.M., Berman, S., Naliboff, B.D., Suyenobu, B.Y.,
Mandelkern, M., and Mayer, E.A. (2004). The neural correlates of placebo
effects: a disruption account. Neuroimage 22, 447–455.
Lorenz, J., Minoshima, S., and Casey, K.L. (2003). Keeping pain out of mind:
the role of the dorsolateral prefrontal cortex in pain modulation. Brain 126,
1079–1091.
Matre, D., Casey, K.L., and Knardahl, S. (2006). Placebo-induced changes in
spinal cord pain processing. J. Neurosci. 26, 559–563.
Mayberg, H.S., and Frost, J.J. (1990). Opiate receptors. In Quantitative
Imaging: Neuroreceptors, Neurotransmitters, and Enzymes, J.J. Frost and
H.N. Wagner, Jr., eds. (New York, NY: Raven Press), pp. 81–95.
Millan, M.J. (2002). Descending control of pain. Prog. Neurobiol. 66, 355–474.542 Neuron 63, 533–543, August 27, 2009 ª2009 Elsevier Inc.Miller, E.K. (2000). The prefrontal cortex and cognitive control. Nat. Rev. Neu-
rosci. 1, 59–65.
Miller, E.K., and Cohen, J.D. (2001). An integrative theory of prefrontal cortex
function. Annu. Rev. Neurosci. 24, 167–202.
Montgomery, G.H., and Kirsch, I. (1997). Classical conditioning and the
placebo effect. Pain 72, 107–113.
Morgan, M.M.,Whittier, K.L., Hegarty, D.M., and Aicher, S.A. (2008). Periaque-
ductal gray neurons project to spinally projecting GABAergic neurons in the
rostral ventromedial medulla. Pain 140, 376–386.
Naidich, T.P., Duvernoy, H.M., Delman, B.N., Sorensen, A.G., Kollias, S.S.,
and Haacke, E.M. (2009). Duvernoy’s Atlas of the Human Brain Stem and
Cerebellum (Vienna: SpringerWienNewYork).
Napadow, V., Dhond, R., Kennedy, D., Hui, K.K.S., and Makris, N. (2006).
Automated brainstem co-registration (ABC) for MRI. Neuroimage 32,
1113–1119.
Nichols, T., Brett, M., Andersson, J., Wager, T., and Poline, J.-B. (2005). Valid
conjunction inference with the minimum statistic. Neuroimage 25, 653–660.
Ochsner, K.N., andGross, J.J. (2005). The cognitive control of emotion. Trends
Cogn. Sci. 9, 242–249.
Padlubnaya, D.B., Parekh, N.H., and Brown, T.H. (2006). Neurophysiological
theory of kamin blocking in fear conditioning. Behav. Neurosci. 120, 337–352.
Pascalis, V.D., Chiaradia, C., and Carotenuto, E. (2002). The contribution of
suggestibility and expectation to placebo analgesia phenomenon in an exper-
imental setting. Pain 96, 393–402.
Petrovic, P., and Ingvar, M. (2002). Imaging cognitive modulation of pain pro-
cessing. Pain 95, 1–5.
Petrovic, P., Kalso, E., Petersson, K.M., and Ingvar, M. (2002). Placebo and
opioid analgesia–imaging a shared neuronal network. Science 295, 1737–
1740.
Petrovic, P., Petersson, K.M., Hansson, P., and Ingvar, M. (2004). Brainstem
involvement in the initial response to pain. Neuroimage 22, 995–1005.
Petrovic, P., Pleger, B., Seymour, B., Klo¨ppel, S., Martino, B.D., Critchley, H.,
and Dolan, R.J. (2008). Blocking central opiate function modulates hedonic
impact and anterior cingulate response to rewards and losses. J. Neurosci.
28, 10509–10516.
Price, D.D., Milling, L.S., Kirsch, I., Duff, A., Montgomery, G.H., and Nicholls,
S.S. (1999). An analysis of factors that contribute to the magnitude of placebo
analgesia in an experimental paradigm. Pain 83, 147–156.
Price, D.D., Craggs, J., Verne, G.N., Perlstein, W.M., and Robinson, M.E.
(2007). Placebo analgesia is accompanied by large reductions in pain-related
brain activity in irritable bowel syndrome patients. Pain 127, 63–72.
Price, D.D., Finniss, D.G., and Benedetti, F. (2008). A comprehensive review of
the placebo effect: recent advances and current thought. Annu. Rev. Psychol.
59, 565–590.
Rainville, P., Duncan, G.H., Price, D.D., Carrier, B., and Bushnell, M.C. (1997).
Pain affect encoded in human anterior cingulate but not somatosensory
cortex. Science 277, 968–971.
Schweinhardt, P., Seminowicz, D.A., Jaeger, E., Duncan, G.H., and Bushnell,
M.C. (2009). The anatomy of the mesolimbic reward system: a link between
personality and the placebo analgesic response. J. Neurosci. 29, 4882–4887.
Scott, D.J., Stohler, C.S., Egnatuk, C.M., Wang, H., Koeppe, R.A., and
Zubieta, J.-K. (2007). Individual differences in reward responding explain
placebo-induced expectations and effects. Neuron 55, 325–336.
Scott, D.J., Stohler, C.S., Egnatuk, C.M., Wang, H., Koeppe, R.A., and
Zubieta, J.-K. (2008). Placebo and nocebo effects are defined by opposite
opioid and dopaminergic responses. Arch. Gen. Psychiatry 65, 220–231.
Valet, M., Sprenger, T., Boecker, H., Willoch, F., Rummeny, E., Conrad, B.,
Erhard, P., and Tolle, T.R. (2004). Distractionmodulates connectivity of the cin-
gulo-frontal cortex and the midbrain during pain–an fMRI analysis. Pain 109,
399–408.
Vase, L., Robinson, M.E., Verne, G.N., and Price, D.D. (2005). Increased
placebo analgesia over time in irritable bowel syndrome (IBS) patients is
Neuron
Placebo Analgesia and Descending Pain Controlassociated with desire and expectation but not endogenous opioid mecha-
nisms. Pain 115, 338–347.
Wager, T.D., Rilling, J.K., Smith, E.E., Sokolik, A., Casey, K.L., Davidson, R.J.,
Kosslyn, S.M., Rose, R.M., and Cohen, J.D. (2004). Placebo-induced changes
in FMRI in the anticipation and experience of pain. Science 303, 1162–1167.
Wager, T.D., Matre, D., and Casey, K.L. (2006). Placebo effects in laser-
evoked pain potentials. Brain Behav. Immun. 20, 219–230.
Wager, T.D., Scott, D.J., and Zubieta, J.-K. (2007). Placebo effects on
human mu-opioid activity during pain. Proc. Natl. Acad. Sci. USA 104,
11056–11061.
Wagner, K.J., Sprenger, T., Kochs, E.F., To¨lle, T.R., Valet, M., and Willoch, F.
(2007). Imaging human cerebral pain modulation by dose-dependent opioidanalgesia: a positron emission tomography activation study using remifentanil.
Anesthesiology 106, 548–556.
Wiech, K., Ploner, M., and Tracey, I. (2008). Neurocognitive aspects of pain
perception. Trends Cogn. Sci. 12, 306–313.
Willer, J.C., Boureau, F., and Albe-Fessard, D. (1979). Supraspinal influences
on nociceptive flexion reflex and pain sensation in man. Brain Res. 179, 61–68.
Zubieta, J.K., Smith, Y.R., Bueller, J.A., Xu, Y., Kilbourn, M.R., Jewett, D.M.,
Meyer, C.R., Koeppe, R.A., and Stohler, C.S. (2001). Regional mu opioid
receptor regulation of sensory and affective dimensions of pain. Science
293, 311–315.
Zubieta, J.-K., Bueller, J.A., Jackson, L.R., Scott, D.J., Xu, Y., Koeppe, R.A.,
Nichols, T.E., and Stohler, C.S. (2005). Placebo effects mediated by endoge-
nous opioid activity on mu-opioid receptors. J. Neurosci. 25, 7754–7762.Neuron 63, 533–543, August 27, 2009 ª2009 Elsevier Inc. 543
